Company
Iovance Biotherapeutics
Iovance Biotherapeutics has 17 drugs tracked on RxWires: 1 in Phase 3, 6 in Phase 2, 3 in Phase 1/2, 7 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Lifileucel plus Pembrolizumab | Phase 3 | Metastatic Melanoma |
| Lifileucel | Phase 2 | Endometrial Cancer |
| Aldesleukin | Phase 2 | Bone Sarcoma |
| E7 TCR-T cells | Phase 2 | Cervical Cancer |
| LN-145 | Phase 2 | Cutaneous Squamous Cell Carcinoma |
| Tumor infiltrating lymphocytes (TIL) LN-145 | Phase 2 | Metastatic Triple Negative Breast Cancer |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL | Phase 2 | Malignant Solid Neoplasm |
| IOV-3001 | Phase 1/2 | Unresectable Melanoma |
| IOV-4001 | Phase 1/2 | Unresectable Melanoma |
| IOV-5001 | Phase 1/2 | Advanced Solid Tumors |
| LN-145/LN-144 | Phase 1 | Soft Tissue Sarcoma |
| Cyclophosphamide | Phase 1 | Locally Advanced Melanoma |
| locally manufactured adoptive cellular therapy (ACT) product | Phase 1 | Malignant Pleural Effusion |
| Resection of PET (high) and PET (low) Tumors | Phase 1 | Unresectable or Metastatic Melanoma |
| IOV-2001 | Phase 1 | Chronic Lymphocytic Leukemia |
| LN-144 | Phase 1 | Stage IIIB Melanoma |
| KK-LC-1 TCR-T cells | Phase 1 | Gastric Cancer |
Latest
- iovance biotherapeutics filed 8-K
- iovance biotherapeutics filed 8-K
- iovance biotherapeutics filed 8-K
- iovance biotherapeutics filed 8-K
- iovance biotherapeutics filed 8-K
Follow Iovance Biotherapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.